Sleep Apnea, Obstructive / Obesity / Overweight · Phase 3 Trial

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

ClinicalTrials.gov · September 8, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a Phase 3 registration for eloralintide, a candidate treatment for obstructive sleep apnea in patients with obesity or overweight, designed as two independent substudies stratified by PAP therapy status. No efficacy or safety results are posted in this registry record; the trial is currently recruiting and outcome data will not be available until study completion.

What was studied

Phase 3, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Sleep Apnea, Obstructive, Obesity, Overweight; age from 18 Years. Intervention: Eloralintide (YSA1); Eloralintide (YSA2). Compared with: Placebo (YSA1) — Placebo Comparator; Placebo (YSA2) — Placebo Comparator. n = 800. 115 sites across 11 countries.

Key findings

Safety

This is a registry record only; no efficacy or safety results are reported. Long-term safety and durability of response beyond 76 weeks are not addressed in this registration.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is an active Phase 3 trial registration with no results posted; the study design and primary endpoints are defined but efficacy and safety data are not yet available.

Study design

As stated by the source record.

MethodsPrimary outcome measures: Percent Change from Baseline in Body Weight (assessed at Baseline, Week 64); Change from Baseline in Apnea-Hypopnea Index (AHI) (assessed at Baseline, Week 64)

DesignPhase 3, Interventional, Randomized, Parallel, Double masking, Treatment purpose

PopulationSleep Apnea, Obstructive, Obesity, Overweight; age from 18 Years

Sample size800

InterventionEloralintide (YSA1); Eloralintide (YSA2)

ComparatorPlacebo (YSA1) — Placebo Comparator; Placebo (YSA2) — Placebo Comparator

Setting115 sites across 11 countries

Reported figures

Quoted from the source exactly as published.

Planned enrollment800

Study phasePHASE 3

Primary outcome measure 1Percent Change from Baseline in Body Weight, Baseline to Week 64

Primary outcome measure 2Change from Baseline in Apnea-Hypopnea Index (AHI), Baseline to Week 64

Study durationapproximately 76 weeks

Caveats

This is a registry record only; no efficacy or safety results are reported.
Recruitment is ongoing; final enrollment and outcomes are not yet available.
Subgroup analyses and comparative effectiveness between YSA1 and YSA2 substudies are not yet defined in this record.
Long-term safety and durability of response beyond 76 weeks are not addressed in this registration.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

strong

Phase 3, randomized, placebo-controlled, parallel-group interventional design.

Directness

strong

Hard clinical endpoints: body weight change and apnea-hypopnea index at 64 weeks.

Consistency

insufficient

No results reported; consistency cannot be assessed from registry record alone.

Risk of bias

insufficient

Registry record does not detail blinding, allocation concealment, or outcome ascertainment methods.

Sample adequacy

moderate

Estimated 800 participants; appears adequate for Phase 3 but final enrollment not yet reported.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07369011). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 800 participants (ESTIMATED). Conditions: Sleep Apnea, Obstructive, Obesity, Overweight. Interventions: DRUG: Eloralintide; DRUG: Placebo. Primary outcome measures: Percent Change from Baseline in Body Weight , Baseline, Week 64; Change from Baseline in Apnea-Hypopnea Index (AHI) , Baseline, Week 64. Brief summary: The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Sleep Apnea, ObstructiveEli Lilly and CompanyNCT07369011ObesityOverweightEloralintide